Skip to main content
Premium Trial:

Request an Annual Quote

Celera, Abbott To Seek Genetic Markers of Response to Abbott Compound

NEW YORK (GenomeWeb News) – Celera and Abbott are collaborating on a project to identify genetic markers for an undisclosed investigational compound under development at Abbott, Celera said today.
The partners plan to determine whether genetic variants Celera has identified can predict how patients may respond to treatment with the drug.
Under the terms of this collaboration, Abbott will pay Celera an undisclosed fee to perform the study. Any companion diagnostic product resulting from the study could be developed by Celera and commercialized through its ongoing alliance with Abbott.
“The results of this study will provide new information on the correlation between genetic markers associated with disease and response to therapy,” said Thomas White, chief scientific officer at Celera, in a statement. “Routinely testing this general concept in early clinical trials may give us new and important insights to personalizing disease management.”

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.